Home › Research › Tau biomarkers
Robustness of Plasma P-Tau217 Diagnostic Thresholds for Alzheimer Disease Across Various Clinical Populations and Laboratory Environments
Bayart JL, Villain N, Planche V, Boyer E, Colmant L, Le Ber I, Picard G, Clot F et al.. Neurology, 2026-11-16
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
We compared Lumipulse p-tau217 with other BBMs; evaluated amyloid-anchored thresholds across centers, analyzers, reagent lots, and clinical populations; and assessed second-line CSF adjudication of gray zone results. Results Among 411 participants (mean age 70.5 years; 51.6% female), p-tau217 showed the best diagnostic performance; p-tau217/Aβ42 did not improve performance or reduce gray zones.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bayart, J. L., Villain, N., Planche, V., Boyer, E., Colmant, L., Le Ber, I., et al. (2026). Robustness of Plasma P-Tau217 Diagnostic Thresholds for Alzheimer Disease Across Various Clinical Populations and Laboratory Environments. Neurology. https://doi.org/10.1212/wnl.0000000000218784
Vancouver
Bayart JL, Villain N, Planche V, Boyer E, Colmant L, Le Ber I, et al. Robustness of Plasma P-Tau217 Diagnostic Thresholds for Alzheimer Disease Across Various Clinical Populations and Laboratory Environments. Neurology. 2026. doi:10.1212/wnl.0000000000218784. PMID: 43038487.
BibTeX
@article{bayart2026-43038487,
author = {Bayart, J. L. and Villain, N. and Planche, V. and Boyer, E. and Colmant, L. and Le Ber, I. and Picard, G. and Clot, F. and others},
title = {{Robustness of Plasma P-Tau217 Diagnostic Thresholds for Alzheimer Disease Across Various Clinical Populations and Laboratory Environments}},
journal = {Neurology},
year = {2026},
doi = {10.1212/wnl.0000000000218784},
pmid = {43038487},
url = {https://doi.org/10.1212/wnl.0000000000218784}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We compared Lumipulse p-tau217 with other BBMs; evaluated amyloid-anchored thresholds across centers, analyzers, reagent lots, and clinical populations; and assessed second-line CSF adjudication of gray zone results.
- Results Among 411 participants (mean age 70.5 years; 51.6% female), p-tau217 showed the best diagnostic performance; p-tau217/Aβ42 did not improve performance or reduce gray zones.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Participants411
- Effect sizeor 97.5; 51.6%; AUC 0.96
- Evidence strengthModerate
How this study scored 70/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record and institution's track record, so those were left out: it earned 43 of the 61 points we could judge it on, which is 70 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 411 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 43038487) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 43 / 61 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 43 of the 61 points we could judge it on is 70 out of 100. |
| Total | 70 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Tau biomarkers from nearby years
Also tagged “various”
5 studies in the library carry the topic tag “various”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 5 tagged studies.